Literature DB >> 26820147

Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?

Livio Garattini1, Alessandro Curto2, Nick Freemantle3.   

Abstract

Mesh：

Year:  2016        PMID： 26820147     DOI： 10.1007/s40273-015-0377-5

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  12 in total

1.  A comparative analysis of the pharmaceutical market in four European countries.

Authors:  L Garattini; F Salvioni; D Scopelliti; S Garattini
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

2.  The pharmaceutical industry--prices and progress.

Authors:  F M Scherer
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

Review 3.  Modeling in pharmacoeconomic studies: funding sources and outcomes.

Authors:  Livio Garattini; Daniela Koleva; Gianluigi Casadei
Journal:  Int J Technol Assess Health Care       Date:  2010-07       Impact factor: 2.188

4.  What is value in health care?

Authors:  Michael E Porter
Journal:  N Engl J Med       Date:  2010-12-08       Impact factor: 91.245

Review 5.  Pricing medicines: theory and practice, challenges and opportunities.

Authors:  Nigel Gregson; Keiron Sparrowhawk; Josephine Mauskopf; John Paul
Journal:  Nat Rev Drug Discov       Date:  2005-02       Impact factor: 84.694

Review 6.  Common methodological flaws in economic evaluations.

Authors:  Michael Drummond; Mark Sculpher
Journal:  Med Care       Date:  2005-07       Impact factor: 2.983

7.  Reference drug programs: effectiveness and policy implications.

Authors:  Sebastian Schneeweiss
Journal:  Health Policy       Date:  2006-06-13       Impact factor: 2.980

8.  Health technology assessment: for whom the bell tolls?

Authors:  Livio Garattini; Gianluigi Casadei
Journal:  Eur J Health Econ       Date:  2008-11

9.  Market-access agreements for anti-cancer drugs.

Authors:  Katelijne van de Vooren; Alessandro Curto; Nick Freemantle; Livio Garattini
Journal:  J R Soc Med       Date:  2014-12-08       Impact factor: 5.344

10.  Italian risk-sharing agreements on drugs: are they worthwhile?

Authors:  Livio Garattini; Alessandro Curto; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2015-01
View more
  10 in total

1.  Comment on: 'The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study'.

Authors:  Livio Garattini; Anna Padula
Journal:  Pharmacoeconomics       Date:  2019-10       Impact factor: 4.981

2.  Market approval for drugs in the EU: time to change direction?

Authors:  Alessandro Curto; Katelijne van de Vooren; Livio Garattini
Journal:  Eur J Health Econ       Date:  2017-11

3.  Pharmaceutical pricing conundrum: time to get rid of it?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2018-11

4.  Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?

Authors:  Jorge Mestre-Ferrandiz; Néboa Zozaya; Bleric Alcalá; Álvaro Hidalgo-Vega
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

5.  Reimbursable drug classes and ceilings in Italy: why not only one?

Authors:  Livio Garattini; Alessandro Curto; Anna Padula
Journal:  Eur J Health Econ       Date:  2016-11

6.  European Medicines Agency: leave the UK but remain the same.

Authors:  Livio Garattini; Alessandro Curto
Journal:  J R Soc Med       Date:  2016-09       Impact factor: 5.344

7.  Competition in pharmaceuticals: more product- than price-oriented?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2018-01

8.  Patient empowerment in Europe: is no further research needed?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2018-06

9.  Pricing vaccines and drugs in Europe: worth differentiating?

Authors:  Livio Garattini; Anna Padula; Nicholas Freemantle
Journal:  Eur J Health Econ       Date:  2021-12

10.  Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting.

Authors:  Simon van der Pol; Paula Rojas Garcia; Fernando Antoñanzas Villar; Maarten J Postma; Antoinette D I van Asselt
Journal:  Pharmacoeconomics       Date:  2021-11-01       Impact factor: 4.981
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.